Marshall Wace LLP Has $277,000 Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Marshall Wace LLP decreased its holdings in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 90.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,917 shares of the company's stock after selling 529,645 shares during the quarter. Marshall Wace LLP's holdings in Humacyte were worth $277,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Rather & Kittrell Inc. acquired a new stake in Humacyte in the 4th quarter valued at about $88,000. Rossby Financial LCC acquired a new position in Humacyte in the 4th quarter worth $126,000. Walleye Capital LLC acquired a new position in Humacyte in the fourth quarter worth $539,000. XTX Topco Ltd lifted its position in Humacyte by 29.0% in the fourth quarter. XTX Topco Ltd now owns 43,929 shares of the company's stock worth $222,000 after purchasing an additional 9,880 shares during the period. Finally, Rockefeller Capital Management L.P. purchased a new stake in Humacyte during the fourth quarter valued at about $251,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Stock Performance

NASDAQ:HUMA traded down $0.02 during mid-day trading on Thursday, reaching $1.21. The stock had a trading volume of 2,018,620 shares, compared to its average volume of 3,626,278. The business has a 50 day simple moving average of $2.03 and a 200 day simple moving average of $3.68. Humacyte, Inc. has a twelve month low of $1.15 and a twelve month high of $9.97. The firm has a market capitalization of $186.92 million, a price-to-earnings ratio of -0.90 and a beta of 1.64.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.07. The firm had revenue of $7.23 million during the quarter, compared to analysts' expectations of $0.64 million. As a group, sell-side analysts expect that Humacyte, Inc. will post -1.27 earnings per share for the current year.

Insider Transactions at Humacyte

In other Humacyte news, CFO Dale A. Sander purchased 20,000 shares of Humacyte stock in a transaction that occurred on Thursday, April 10th. The stock was purchased at an average price of $1.53 per share, with a total value of $30,600.00. Following the completion of the acquisition, the chief financial officer now owns 40,600 shares of the company's stock, valued at approximately $62,118. This trade represents a 97.09 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kathleen Sebelius bought 50,000 shares of the business's stock in a transaction on Tuesday, April 8th. The stock was acquired at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the transaction, the director now owns 91,207 shares in the company, valued at $120,393.24. This represents a 121.34 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 83,993 shares of company stock worth $118,224 in the last three months. Company insiders own 11.20% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on HUMA. HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Humacyte in a research note on Wednesday, March 12th. Benchmark reaffirmed a "buy" rating on shares of Humacyte in a research report on Thursday, February 27th. Finally, D. Boral Capital reiterated a "buy" rating and set a $25.00 price target on shares of Humacyte in a report on Wednesday, March 26th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.